| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NLS1878AF405 | |||
| Alexa Fluor 488 | NLS1878AF488 | |||
| Alexa Fluor 647 | NLS1878AF647 | |||
| Alexa Fluor 700 | NLS1878AF700 | |||
| Biotin | NLS1878B | |||
| DyLight 405 | NLS1878V | |||
| DyLight 488 | NLS1878G | |||
| DyLight 550 | NLS1878R | |||
| DyLight 650 | NLS1878C | |||
| FITC | NLS1878F | |||
| HRP | NLS1878H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-33337SS | |||
| Azide and BSA Free | NBP2-80656 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22217SS | |||
| Azide and BSA Free | NBP2-80825 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77080SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-540SS | |||
| Azide and BSA Free | NBP2-80677 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76701SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1475SS | |||
| Azide and BSA Free | NBP2-80640 | |||
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0012.jpg "Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Mouse J774A.1, mouse reticulum cell sarcoma macrophage cell line. Left panel is + Anti-Rabbit FITC; middle panel indicates the cell nuclei stained with Hoechst; the right panel is a merged image. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0008.jpg)
![Immunohistochemistry-Paraffin: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - SPM receptors differentially expressed on endothelium and infiltrating leukocytes AE](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NLS1878-img0011.jpg)
![Flow Cytometry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Flow Cytometry: [Alexa Fluor® 700] [NLS1878AF700] - Mouse splenocytes. Cells were pre-gated with live/dead and FSC-A/W to exclude dead cells and cell doublets. Image from verified customer review. Image using the Alexa Fluor 700 form of this antibody.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Flow-Cytometry-NLS1878-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Murine neutrophils were extracted from the bone marrow of C57BL/6 mice and exposed to normal glucose (90 mg/dl) or high glucose (300 mg/dl) and the expression of FPR2 was assessed by western blotting after 1, 2, or 3 hr exposure to glucose. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35112667/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2 Antibody - BSA Free-Western Blot-NLS1878-img0013.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in HL-60 cell lysate.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Antibody was tested in Raw264.7 cells with DyLight 488 (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0005.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in human kidney cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-NLS1878-img0006.jpg)
![Electron Microscopy: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c=50A nm, e=100A nm. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Electron-Microscopy-NLS1878-img0010.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382420.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534335.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534380.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382435.jpg)
![Immunocytochemistry/ Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Lipoxin A4, along with its precursors & ligand, were altered by hAECs. (A): Expression of the lipoxin A4 precursor genes ALOX‐5, ‐12, & ‐15 was increased at days 5 & 7 compared with saline controls (ALOX‐5: 0.393 ± 0.114 vs. 3.777 ± 1.98; ALOX‐12: 0.484 ± 0.248 vs. 1.520 ± 0.203; ALOX‐15: 0.020 ± 0.007 vs. 1.998 ± 0.983). ∗, p < .05. (B): Lipoxin A4 protein levels were elevated in lung lysates at day 7 in animals treated with hAECs compared with controls (0.103 ± 0.021 ng/ml vs. 0.249 ± 0.072 ng/ml, respectively). ∗, p < .05. (C): At day 7, bleomycin challenge resulted in positively stained F4/80/FPR2 cells, which were was elevated in mice treated with hAECs compared with control mice (5.720% ± 0.587% vs. 8.795% ± 0.687%, respectively). ∗, p < .05. (D): Representative images of F4/80‐ & FPR2‐positive‐stained lung sections from hAEC‐treated animals. Magnification: ×200. Scale bar =100 μm. Abbreviations: DAPI, 4′,6‐diamidino‐2‐phenylindole; FPR2, N‐formyl peptide receptor 2; hAEC, human amnion epithelial cell. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28371562), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202416114742.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Higher expression of Fpr2 in the livers of female mice is related with hepatocyte protection.a qRT-PCP analysis for Fpr2 expression in primary hepatocytes (pHEPs) from WT (male n = 2, female n = 2) & KO mice (male n = 2, female n = 2). Total eight mice were employed in each hepatocyte isolation, & the experiments were replicated at least three times & the mean ± S.E.M. results are graphed (*p < 0.05, **p < 0.005 vs WT male-pHEPs). b Western blot analysis & c double immunofluorescent images of Fpr2 (red) with albumin (green) in these cells. Gapdh was used as internal control. DAPI (blue) was used as nuclear counterstaining. Data shown represent one of three experiments with similar results (Scale bar, 20 μm). d qRT-PCR analysis for Fpr2 & glucose-6-phosphatase (G6pc) in, e cell viability of, & f western blot analysis of cleaved Caspase-3 & pro Caspase-3 in WT & KO female mice-isolated pHEPs treated with vehicle (Veh) or 250 μM of palmitate (PA). The data shown represent one of three experiments with similar results. The mean ± S.E.M. results obtained from three repetitive experiments are graphed (*p < 0.05, **p < 0.005 vs WT-Veh). Gray circles represent individual data points. See Supplementary Data for statistical details. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35102146), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-3102024161228.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Mouse spleen cryosection.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Immunohistochemistry-Paraffin-NBP2-33337-img0009.jpg "Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Mouse spleen cryosection.")
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Mouse spleen.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Immunohistochemistry-Paraffin-NBP2-33337-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Wehi-3 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti CD68 (FA-11) [NBP2-33337] at a 1:100 dilution overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Immunocytochemistry-Immunofluorescence-NBP2-33337-img0012.jpg)
![Flow (Intracellular): CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - An intracellular stain was performed on Raw 246.7 cells with CD68/SR-D1 (FA-11) antibody NBP2-33337 (blue) and a matched isotype control MAB006 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by DyLight488-conjugated anti-rat secondary antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Flow-Intracellular-NBP2-33337-img0011.jpg)
![Western Blot: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Expression on J774 cells.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Western-Blot-NBP2-33337-img0010.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - An intracellular stain was performed on Raw264.7 cells with CD68/SR-D1 Antibody (FA-11) NBP2-33337B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Flow-Cytometry-NBP2-33337-img0013.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Staining of permeabilised Mouse peritoneal Macrophages cells with Rat anti Mouse CD68 Antibody (Clone FA-11) visualised with F(ab')2 Goat Anti Rat IgG:FITC (Mouse Adsorbed).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Flow-Cytometry-NBP2-33337-img0007.jpg)
![Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0001.jpg "Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.")
![Immunohistochemistry-Frozen: CD3 Antibody (SP7) [NB600-1441] - T-cells and microglia in mouse spinal cord with acute EAE. Mouse was perfused with 4% paraformaldehyde. Spinal cord was post-fixed overnight, followed by cryoprotection with 30% sucrose for 24h. Spinal cord sections were treated with antigen-retrieval buffer (pH 6.0) at 60C for 10 min, then cooled down to room temperature (this step should not be omitted). Anti-CD3 antibody was diluted at 1:200. Incubation: room temperature overnight. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Frozen-NB600-1441-img0002.jpg)
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - Mouse lung tissue stained against C3aR normal conditions (left) and knockdown conditions (right). IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0003.jpg)
![TLR4 Inhibitor Peptide Set [NBP2-26244] - The inhibitor peptide inhibits TLR4 signaling by blocking interactions between TLR4 and its adaptors Mal/TIRAP and TRAM.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-NBP2-26244-img0013.jpg "TLR4 Inhibitor Peptide Set [NBP2-26244] - The inhibitor peptide inhibits TLR4 signaling by blocking interactions between TLR4 and its adaptors Mal/TIRAP and TRAM.")
![Blocking/Neutralizing: TLR4 Inhibitor Peptide Set [NBP2-26244] - iBMDM cultures were pretreated with 5uM of inhibitor or control prior to stimulation with 20 ng/ml LPS. Negative (LPS-, LPS-/CP7+, LPS-/CP7+) and positive (LPS+) controls were also included. Supernatants were harvested after 6 h and murine TNF-alpha measured by ELISA. TLR4 inhibitor, but not the control, inhibited LPS-induced TNF-alpha production. Image courtesy of Dr. Julianne Stack and Dr. Andrew Bowie, Trinity College, Dublin, Ireland.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26244-img0015.jpg)
![TLR4 Inhibitor Peptide Set [NBP2-26244] - TLR4/MD-2/CD14/NF-kB/SEAPorter stably transfected cells were plated in 96-well plates at 1x10^5 cells/well. After 16 h, cells were preincubated with various concentrations of inhibitor or control peptides (CP) for 1 h. Cells were then stimulated with 10 ng/ml LPS for 24 h. The secreted alkaline phosphatase (SEAP) was analyzed using the SEAPorter Assay Kit. Inhibitory effect on the LPS-mediated TLR4 activation by the VIPER peptide is shown in panel A, and IC50 of the VIPER peptide is described in panel B.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26244-img0016.jpg)
![Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.](http://images.novusbio.com/fullsize/Rabbit-IgG-Isotype-Control-Immunohistochemistry-Frozen-NB810-56910-img0012.jpg "Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.")
![Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.](http://images.novusbio.com/fullsize/Rabbit-IgG-Isotype-Control-Immunohistochemistry-Frozen-NB810-56910-img0011.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and LAMP2 knockout (KO) HeLa cell line. PVDF membrane was probed with Mouse Anti-Human LAMP-2/CD107b (H4B4) Monoclonal Antibody (Catalog # NBP2-22217) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for LAMP-2/CD107b at approximately 100 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Knockout-Validated-NBP2-22217-img0016.jpg "<b>Genetic Strategies Validation. </b>Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and LAMP2 knockout (KO) HeLa cell line. PVDF membrane was probed with Mouse Anti-Human LAMP-2/CD107b (H4B4) Monoclonal Antibody (Catalog # NBP2-22217) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for LAMP-2/CD107b at approximately 100 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Immunofluorescence: [Alexa Fluor® 647] [NBP2-22217AF647] - T98G glioblastoma cells grown on #1.5 coverglass stained with a conjugated LAMP-2/CD107b (H4B4)AF647 antibody, counterstained with DAPI. Cathepsin D (green) staining also visible. This image was submitted via customer Review. Image using the Alexa Fluor 647 form of this antibody.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Immunocytochemistry-Immunofluorescence-NBP2-22217-img0015.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Analysis of LAMP-2/CD107b expression in Whole Cell Lysates: 2) HeLa, 3) Jurkat, 4) U937, 5) HepG2, Tissue Extracts: 6) Human kidney, 7) Human lung, 8) Human liver, and 9) Human placenta.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Western-Blot-NBP2-22217-img0003.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Staining of LAMP-2/CD107b in human liver using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Immunohistochemistry-Paraffin-NBP2-22217-img0001.jpg)
![Flow Cytometry: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - An intracellular stain was performed on U937 cells with HGF LAMP-2/CD107b [H4B4] Antibody NBP2-22217AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Flow-Cytometry-NBP2-22217-img0017.jpg)
![Simple Western: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lane view shows a specific band for LAMP-2/CD107b in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Simple-Western-NBP2-22217-img0005.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Localization of TMEM135 to the mitochondria. The mitochondrial fraction isolated from the WT mouse brain show TMEM135 signals by immunoblotting. Following proteins were used as organelle markers: MFN2-mitochondria; LAMP2-lysosome; Lamin B1- nucleus; PDI- endoplasmic reticulum (ER). Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/19264), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Western-Blot-NBP2-22217-img0019.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Representative pictures of effect of I/R on DNA damage, cell survival, and inflammation. Western blot analysis expression level of Cathepsin B (*P < 0.05) in total protein extract from RVA of I/R treated vs. control group. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fphar.2018.01034/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Western-Blot-NBP2-22217-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-LAMP-2/CD107b [NBP2-22217] at a 1:100 dilution overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Immunocytochemistry-Immunofluorescence-NBP2-22217-img0008.jpg)
![Flow Cytometry: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Intracellular flow cytometric staining of 1 x 10^6 HEK-293 cells using anti-LAMP-2/CD107b (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Flow-Cytometry-NBP2-22217-img0004.jpg)
![ELISA: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Anti-LAMP-2/CD107b was used to assess lysates from human SVG-A cells via ELISA, by loading the indicated mass of total protein per well. Antibodies tested were diluted 1:250, and used in conjunction with an HRP-conjugated secondary antibody. Signal was detected by luminescence. Image from verified customer review.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-ELISA-NBP2-22217-img0014.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0011.jpg "Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Staining of NALP3 in K562 cells with NALP3 antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0010.jpg)
![Immunohistochemistry-Paraffin: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in mouse lung tissue using anti-NALP3 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NBP1-77080-img0003.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in K562 cell lysate with NALP3 antibody at 1 ug/mL (A) in the absence and (B) in the presence of blocking peptide.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0009.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. Representative image of immunofluorescent staining of NLRP3 related genes in corneal and conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3 Antibody - BSA Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0012.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. (A) Representative image of immunofluorescent staining of NLRP3 related genes in corneal & conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). (B,C) qRT-PCR showed the mRNA levels of NLRP3 related genes in conjunctiva & cornea (four corneas/conjunctivas were mixed as a sample). Data was shown as mean ± SEM. *p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241535675.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of exogenous rHMGB1 significantly promoted the mRNA & protein production of NLRP3 (a, c) & ASC (e, g) & activation of caspase-1 (i). Thus, the intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed the production of NLRP3 (b, d) & ASC (f, h) & activation of caspase-1 (j). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415345338.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Co-immunoprecipitation assay: Figure showing interaction of NLRP3, NLRC4 & NAIP with ASC during CFT073 infection in THP-1m. Cytoplasmic extracts of THP-1m infected with or without CFT073, 6 h post stimulation were subjected to IP & WB by various antibodies (ASC, NLRP3, NLRC4, & NAIP) as described in material & methods. Cytoplasmic extract used as input was subjected to check NLRP3, ASC, NLRC4 & NAIP expression as shown in figure. ASC antibody was used to co-immunoprecipitate the complex from cytoplasmic extracts & then immunoblotted to detect NLRP3, NLRC4 & NAIP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31551961), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415371971.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 regulated the activation of NLRP3, rather than the activation of caspase-8, via NF-kappa B pathway. a, b NF-kappa B was activated in ischemic retina at the early stage after reperfusion. c, d Intraocular injection rHMGB1 or GA could promote or suppress the production of phosphor-NF-kappa B p65. e, f Intravitreal injection of NF-kappa B p65 inhibitor, JSH-23, significantly reduced the activation of NLRP3 & decreased the processing of IL-1 beta , g rather than caspase-8. However, intravitreal injection of caspase-8 inhibitor, Z-IETD-fmk, decreased the production of phosphor-NF-kappa B p65, obviously (h). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415291993.jpg)
![Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Intracellular-NB200-540-img0005.jpg "<b>Biological Strategies Validation. </b>Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Complement C3 Antibody (11H9) [NB200-540] - C3 protein fragments deposited on kidney cells of MPL-lpr mouse. Staining with antibody 11H9. Glomerular staining pattern. Fixation in 4% paraformaldehyde in PBS pH 7.4. Vibratome sections of 4 um. Pretreated with 3% hydrogen peroxide for 20 min to quench endogenous peroxidases. Microwaved in antigen unmasking solution for 2-5 minutes as antigen retrieval.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunocytochemistry-Immunofluorescence-NB200-540-img0002.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse liver using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. Weak but distinct membrane-cytoplasmic immunopositivity was observed in hepatocytes and few cells developed punctate membrane staining.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0004.jpg)
![Flow Cytometry: Complement C3 Antibody (11H9) [NB200-540] - Left panel: FMO, Middle panel: No primary antibody control, Right panel: sample. Day 6 murine mammary tumors processed and stained for analysis with flow cytometry. The C3b+ population of CD45+ cells is what the gate in each sample is exhibiting. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Cytometry-NB200-540-img0006.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse lymph node using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. This representative photomicrograph shows a membrane-cytoplasmic immunopositivity in non-germinal center cells, and few cells developed an intense staining for this target protein.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0003.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0016.jpg "<b>Biological Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Analysis of human uterus tissue using anti-TIM-1 antibody (3809) at 10 ug/ml.Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 C. A goat anti-rabbit IgG H&L (HRP)at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Immunohistochemistry-Paraffin-NBP1-76701-img0013.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of NIH/3T3 cell lysates. Antibodies: TIM-1 3809 (8 ug/mL), overnight incubation at 4 C in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0010.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of lysates per lane. Antibodies: TIM-1 3809 (8 ug/mL), TIM-13811 (1 ug/mL), beta-actin (1 ug/mL), and GAPDH (0.02 ug/mL), overnightincubation at 4C (3809) or 1h incubation at RT in 5% NFDM/TBST. Secondary:Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0012.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - HeLa cells were transfected with control siRNAs (lane 1) or TIM-1 siRNAs (lane 2) Loading: 15 ug of HeLa whole cell lysates per lane. Antibodies: 3809 (8 ug/mL), 1 hincubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0015.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 u of lysates per lane.Antibodies: TIM-1 (8 u/mL), overnight incubation at 4; C in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-2711202420171718.gif)
![Immunocytochemistry/ Immunofluorescence: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Validation of TIM-1/KIM-1/HAVCR in Human Uterus Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human uterus cells labeling TIM-1/KIM-1/HAVCR with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on human uterus cells.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-271120241937768.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0010.jpg "<b>Biological Strategies Validation. </b>Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC and EA treatment on the expression of mBDNF and NT4 in neurons. Photomicrographs for mBDNF/NeuN or NT4/NeuN double-positive cells in the striatum and hippocampus (n = 5). The number of mBDNF/NeuN double-positive cells in the SVZ + striatum and hippocampus was significantly higher in the EA-treated MCAO group and the combined mBMSC + EA-treated MCAO group, compared to the number in the other groups. The number of NT4/NeuN double-positive cells in the hippocampus was significantly higher in the EA-treated MCAO group than in the vehicle-treated MCAO group. #p < 0.05 and ##p < 0.01 versus control group; *p < 0.05, **p < 0.01, and ***p < 0.001 versus vehicle-treated MCAO group; &&p < 0.01 versus mBMSC-treated MCAO group. Scale bar = 100 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-018-20481-3) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-NB100-98682-img0007.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Human platelet lysate and recombinant mature BDNF. Blocking: 1% LFDM for 30 min at RT; primary antibody (1:1000) incubated at 4C overnight.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0006.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0001.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0003.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0005.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415371951.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415175223.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Antagonized TrkB could restrain the activation of astrocytes & microglia & supress the p38/JNK pathway to alleviate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. Western blots showed that the overexpression of a BDNF, b TrkB, cp-TrkB, d Iba1, e GFAP, fp-p38, gp-JNK, h TNF-alpha , & i IL-1 beta were downregulated in comparison to the CYP + DMSO group after ANA-12 treatment. All data were calculated as mean ± SEM (n = 5 per group). **p < 0.01, ***p < 0.001 vs. control group. ##p < 0.01, ###p < 0.001 vs. CYP + ANA-12 group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415291934.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further & promoted activation of astrocytes & microglia, & enhanced the p38/JNK pathway to aggravate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. a BDNF treated every other day after CYP injection could further lower the mechanical withdrawal threshold & suppress the retrieval of mechanical threshold when compared with the CYP + PBS group. After the exogenous BDNF injection, Western blots showing the expression of b BDNF, c TrkB, dp-TrkB, e Iba1, f GFAP, gp-p38, hp-JNK, i TNF-alpha , & j IL-1 beta were all further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284921.jpg)
![Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC & EA treatment on the expression of trophic factors. (A) Photomicrographs & (B‒D) histograms for mBDNF, NT4, & VEGF expression (n = 4–5). mBDNF expression was markedly increased by treatment with mBMSC and/or EA compared to vehicle treatment. mBDNF expression levels were higher in the EA-treated MCAO group than in the mBMSC-treated MCAO group. NT4 expression in the SVZ & hippocampus was significantly higher in the combined mBMSC & EA treatment group than in the other groups. VEGF expression in the hippocampus was markedly higher in the mBMSC treatment group than in the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, & ###p < 0.001 versus control group; *p < 0.05, **p < 0.01, & ***p < 0.001 versus vehicle-treated MCAO group; &p < 0.05, &&p < 0.01, & &&&p < 0.001 versus mBMSC-treated MCAO group; Scale bar = 1 mm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29391466), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284912.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - The expression of BDNF-TrkB signaling in the SDH of CYP-induced cystitis. a Changes of the mechanical threshold in CYP-induced cystitis model. Compared to that in the control group, the mechanical threshold of the cystitis group decreased significantly after the CYP injection & remained low until day 17, & the minimum threshold value was reached on day 12. The expression of b BDNF, c TrkB, & dp-TrkB were evaluated by western blots. Compared to the control group, they were upregulated on days 8, 12, & 17. e Immunofluorescence double staining assay of BDNF & p-TrkB in the SDH. BDNF & p-TrkB (red), NeuN, GFAP, & OX-42( green), co-localization (yellow). BDNF was mainly colocalized in neurons which mainly located in Laminate II to IV. & TrkB receptors expressed in neurons, microglia, & astrocytes. The white dotted lines in picture “BDNF/NeuN” showed the laminate of the SDH according to Rexed & Steiner. Scale bar = 100 μm. All data were calculated as mean ± SEM (n = 5 per group). *p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284910.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] (NB600-1475) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0019.jpg "Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] (NB600-1475) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - 4T1 tumor sections were stained for CD31 (green) and CD105 (red).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunohistochemistry-Frozen-NB600-1475-img0006.jpg)
![Flow (Cell Surface): CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on WEHI-3 Cells with CD31/PECAM-1 Antibody (MEC13.3) (NB600-1475, blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature, followed by rat F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0113, R&D Systems).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cell-Surface-NB600-1475-img0009.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - C57BL/6 mouse splenocytes stained with purified CD31/PECAM-1 Antibody (MEC13.3), followed by anti-rat IgG FITC](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] conjugated to DyLight 488 (NB600-1475G) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - MS1 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with at 5.0 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - was tested in Wehi-3 cells with Dylight 488 (green). Nuclei and beta-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0011.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - JAK3 colocalized with endothelial cells labeled with CD31. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fneur.2017.00363/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunohistochemistry-Paraffin-NB600-1475-img0015.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS1 cells with CD31/PECAM-1 [MEC13.3] Antibody NB600-1475R (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0022.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] conjugated to Alexa Fluor 647 (NB600-1475AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Mouse MS1 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD31/PECAM-1 Antibody [MEC13.3] conjugated to DyLight 550 (NB600-1475R) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunocytochemistry-Immunofluorescence-NB600-1475-img0018.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - Staining of mouse CD31 in non-small cell lung cancer tumor sections from a human NSCLC tumor-bearing mouse. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Immunohistochemistry-Frozen-NB600-1475-img0012.jpg)
![Flow (Cell Surface): CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on WEHI-3 Cells with CD31 (MEC13.3) antibody NB600-1475 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature, followed by rat F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0113, R&D Systems).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cell-Surface-NB600-1475-img0013.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS-1 cells with CD31/PECAM-1 Antibody (MEC13.3) (NB600-1475AF647, blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0014.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS1 cells with CD31/PECAM-1 [MEC13.3] Antibody NB600-1475DL594 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 594.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0020.jpg)
![Flow Cytometry: CD31/PECAM-1 Antibody (MEC13.3) [NB600-1475] - A surface stain was performed on MS1 cells with CD31/PECAM-1 [MEC13.3] Antibody NB600-1475G (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-MEC13-3-Flow-Cytometry-NB600-1475-img0021.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (MEC13.3) - BSA Free [NB600-1475] - (A) Representative Western blots depicting phosphorylated JAK3 (pJAK3), total JAK3, & corresponding beta -actin levels in the ipsilateral (CXI) versus the contralateral (CXC) cortex at 24 h in sham & mice subjected to permanent middle cerebral artery occlusion (pMCAO). (B,C) Quantified pJAK3 & JAK3 values normalized to beta -actin in the cortex of sham & mice subjected to stroke. Both pJAK3 & JAK3 are significantly increased in the ipsilateral cortex of stroked animals (*P < 0.05 & **P < 0.01 with respect to sham ipsilateral/contralateral & stroke contralateral; sham, n = 5; stroke, n = 13). Data were analyzed using a two-way ANOVA (ipsilateral/contralateral or sham/stroke) with Bonferroni post-test. (D) Diagram showing peri-infarct brain region from which images were taken (n = 3). Scale bar is 10 µm, & magnification is 60×. (E) JAK3 colocalized with microglia/macrophages labeled with Iba-1. (F) JAK3 colocalized with neurons labeled with NeuN. (G) JAK3 colocalized with endothelial cells labeled with CD31. (H) JAK3 is not colocalized with astrocytes labeled with GFAP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28790974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1475_rat-monoclonal-cd31-pecam-1-antibody-mec13-3-310202416171428.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse fore brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0020.jpg "Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse fore brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min")
![Immunocytochemistry/Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 Antibody (1 1:1000, Red) expression in dorsal root ganglia. Green fluorescent Nissl was used as counter-staining. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-19019-img0002.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse cerebellum stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0007.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat brain stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0010.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat cerebellum stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0011.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat hind brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0016.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Analysis of paraffin-embedded human hepatoma, using at 1:500 dilution.Iba1 antibody detects AIF-1/Iba1 in the cytosol of Kupffer cell in human hepatoma by immunohistochemical analysis.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0018.jpg)
![Immunohistochemistry: AIF-1/Iba1 Antibody [NBP2-19019] - LCN2 mainly expressed on neurons. a Representative immunofluorescence images of LCN2 (green) and AIF-1/Iba1 (red) staining in sections of the hippocampus after surgery. Long scale bar, 600 um; short scale bar, 25 um. Image collected and cropped by CiteAb from the following publication (pubmed.ncbi.nlm.nih.gov/35413913) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-2552023153956.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - LCN2 mainly expressed on neurons. a Representative immunofluorescence images of LCN2 (green), GFAP (red), NeuN (red) & IbaI (red) staining in sections of the hippocampus after surgery. Long scale bar, 600 µm; short scale bar, 25 µm. b Percentage quantification of LCN2 positive cells (n = 3 mice/group). c Cartoon depicting MACS sorting procedures for isolating CD11b+ & CD11b − cells. d Relative expression of cx3cr1 in CD11b + & CD11b − cells after sorting from all samples. d Relative expression level of Lcn2 mRNA in CD11b + & CD11b − cells from hippocampus 6 h after surgery. e Relative expression level of IL-6 mRNA in CD11b + cells. Data are represented as mean ± SEM. **** P Sample: Frozen-sectioned mouse brain.Green: AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Blue: Fluoroshield with DAPI .Antigen Retrieval: ice-cold MeOH for 5 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242091448.jpg)
![Western Blot: AIF-1/Iba1 Antibody [NBP2-19019] - Rat tissue extract (50 ug) was separated by 15% SDS-PAGE, and the membrane was blotted with AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:1000.](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242075976.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein by immunohistochemical analysis.Sample: Paraffin-embedded rat tissues.AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:100.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-910202420115036.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein at cell membrane by immunofluorescent analysis.Sample: THP-1 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242011504.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein at cell membrane and cytoplasm by immunohistochemical analysis.Sample: Paraffin-embedded mouse brain.AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-910202419593534.jpg)
![Iba1 antibody detects Iba1 protein expression at microglias by immunohistochemical analysis.Sample: Frozen sectioned E13.5 Rat brain. Green: Iba1 protein stained by Iba1 antibody (NBP2-19019) diluted at 1:250.Red: beta Tubulin 3/ TUJ1, a mature neuron marker, stained by beta Tubulin 3/ TUJ1 antibody [GT11710] diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-immunohistochemistry-frozen-2611202518272320.jpg)
